title: Combined CXCR1/CXCR2 antagonism decreases radiation-induced alveolitis in the mouse.
abstract: The mechanisms leading to the radiation-induced lung responses of alveolitis and fibrosis are largely unknown. Herein we investigated whether CXC receptor 1 and 2 antagonism with CXCL8((3-72))K11R/G31P (G31P), a protein that reduces neutrophil chemotaxis in acute inflammatory response models, decreases the lung response to radiation. Mice of the AKR/J (alveolitis/pneumonitis responding) and KK/HIJ (fibrosis) strains received 18 Gy whole-thorax irradiation and a subset of these mice were treated with G31P (500 µg/kg) three times per week from the day of irradiation until euthanasia due to respiratory distress symptoms or 20 weeks after radiation treatment. Irradiated mice of both strains receiving G31P survived longer than mice receiving radiation alone. Radiation- and G31P-treated AKR/J mice surviving to the end of the experiment developed significantly less alveolitis, as measured histologically, than mice receiving radiation alone, but this difference was not evident in KK/HIJ mice. Using immunohistochemistry, G31P treatment was shown to increase the numbers of Gr-1-positive cells (neutrophils) in the lungs of unirradiated mice relative to control mice injected with saline, but the antagonist did not alter the numbers of Gr-1-positive cells in the lungs of radiation-treated mice. We conclude that G31P treatment reduces radiation-induced alveolitis but not fibrosis in mice.
authors.affiliation: Department of Medicine and the Meakins-Christie Laboratories, McGill University, 3626 St. Urbain Montreal, Quebec, Canada, H2X 2P2.
authors.forename: Jessica
authors.initials: J
authors.lastname: Fox
authors.forename: John R
authors.initials: JR
authors.lastname: Gordon
authors.forename: Christina K
authors.initials: CK
authors.lastname: Haston
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000528:radiation effects; D002452:Cell Count; D005260:Female; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000503:physiopathology; D016209:Interleukin-8 / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects / Q000528:radiation effects; D010446:Peptide Fragments / Q000494:pharmacology* / Q000627:therapeutic use; D010641:Phenotype; D011650:Pulmonary Alveoli / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology / Q000528:radiation effects*; D011658:Pulmonary Fibrosis / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000503:physiopathology; D011833:Radiation Injuries, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D023062:Receptors, Interleukin-8A / Q000037:antagonists & inhibitors*; D023063:Receptors, Interleukin-8B / Q000037:antagonists & inhibitors*; D013909:Thorax / Q000528:radiation effects
chemical_list: C457773:CXCL8(3-73)K11R,G31P, bovine; D016209:Interleukin-8; D010446:Peptide Fragments; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B